Background diabetic retinopathy

This study tests a one-time gene therapy called surabgene lomparvovec (Sura-vec) for diabetic retinopathy, a common eye problem from diabetes that can lead to blindness. About 576 adults with moderate-to-severe non-proliferative diabetic retinopathy will receive either the gene t…

This early-stage trial tests an experimental drug called RO7663498, given as an injection into the eye, for people with diabetic retinopathy. The main goal is to check safety and how the drug moves through the body. About 30 participants will receive multiple doses to see if it i…

This Phase 3 trial tests an implant called OTX-TKI that slowly releases the drug axitinib inside the eye. It aims to stop or slow worsening of non-proliferative diabetic retinopathy, a common diabetes complication that can lead to vision loss. About 930 adults with moderate to se…

This study tests a new drug called ANXV in 12 adults with eye diseases from diabetes or blocked retinal veins. The main goal is to check if ANXV is safe and if it can improve vision or reduce the need for other treatments. Participants receive ANXV as a 30-minute infusion for 5 d…

This study tests the safety of a new drug called IGT-303 in healthy volunteers and people with chronic kidney disease (CKD). About 94 participants will receive either the drug or a placebo, given as a shot under the skin or into a vein. Researchers will monitor for side effects t…

This study follows 100 people with type 2 diabetes who have moderate to severe diabetic retinopathy, a condition that can lead to vision loss. Researchers will use advanced eye scans and imaging to track changes in the retina over two years. The goal is to find better ways to pre…